Cartesian Therapeutics (RNAC) Other Non-Current Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Other Non-Current Liabilities for 11 consecutive years, with $47000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 97.67% year-over-year to $47000.0; the TTM figure through Mar 2026 stood at $47000.0 (down 97.67% YoY), while the FY2025 annual figure was $141000.0, down 96.32% from the prior year.
• Other Non-Current Liabilities slipped to $47000.0 in Q1 2026 per RNAC's latest filing, from $141000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $33.5 million in Q3 2022 and bottomed at $47000.0 in Q1 2026.
• Historically, Other Non-Current Liabilities has averaged $10.0 million across 5 years, with a median of $5.7 million in 2023.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities jumped 236.12% — and 2026, when it sank 97.67%.
• Cartesian Therapeutics' Other Non-Current Liabilities stood at $19.1 million in 2022, then slumped by 70.36% to $5.7 million in 2023, then plunged by 32.39% to $3.8 million in 2024, then tumbled by 96.32% to $141000.0 in 2025, then slumped by 66.67% to $47000.0 in 2026.
• Business Quant data shows RNAC's Other Non-Current Liabilities at $47000.0 in Q1 2026, $141000.0 in Q4 2025, and $848000.0 in Q3 2025.